Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3323 ARTÍCULOS , VIENDO DEL 3091 AL 3105

Using high-resolution MR imaging at 7T to evaluate the anatomy of the midbrain dopaminergic system

Eapen M, Zald DH, Gatenby JC, Ding Z, Gore JC.

AJNR Am J Neuroradiol. 2011 Apr;32(4):688-94. doi: 10.3174/ajnr.A2355. Epub 2010 Dec 23.

General anaesthesia for deep brain stimulator electrode insertion in Parkinson's disease

Sutcliffe AJ, Mitchell RD, Gan YC, Mocroft AP, Nightingale P.

Acta Neurochir (Wien). 2011 Mar;153(3):621-7. doi: 10.1007/s00701-010-0845-9. Epub 2010 Dec 24.

Recent developments in adenosine receptor ligands and their potential as novel drugs

Müller CE, Jacobson KA.

Biochim Biophys Acta. 2011 May;1808(5):1290-308. doi: 10.1016/j.bbamem.2010.12.017. Epub 2010 Dec 23.

Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease

Voutilainen MH, Bäck S, Peränen J, Lindholm P, Raasmaja A, Männistö PT, Saarma M, Tuominen RK.

Exp Neurol. 2011 Mar;228(1):99-108. doi: 10.1016/j.expneurol.2010.12.013. Epub 2010 Dec 24.

Neurodegeneration in glaucoma: progression and calcium-dependent intracellular mechanisms

Crish SD, Calkins DJ.

Neuroscience. 2011 Mar 10;176:1-11. doi: 10.1016/j.neuroscience.2010.12.036. Epub 2010 Dec 25.

What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?

Hilker R, Antonini A, Odin P.

J Neural Transm (Vienna). 2011 Jun;118(6):907-14. doi: 10.1007/s00702-010-0555-8. Epub 2010 Dec 25.

High frequency deep brain stimulation of the subthalamic nucleus versus continuous subcutaneous apomorphine infusion therapy: a review

Carron R, Fraix V, Maineri C, Seigneuret E, Piallat B, Krack P, Pollak P, Benabid AL, Chabardès S.

J Neural Transm (Vienna). 2011 Jun;118(6):915-24. doi: 10.1007/s00702-010-0556-7. Epub 2010 Dec 29.

Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration

Baydyuk M, Nguyen MT, Xu B.

Exp Neurol. 2011 Mar;228(1):118-25. doi: 10.1016/j.expneurol.2010.12.018. Epub 2010 Dec 28.

Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial

Ondo WG, Shinawi L, Davidson A, Lai D.

Parkinsonism Relat Disord. 2011 Mar;17(3):156-9. doi: 10.1016/j.parkreldis.2010.12.003. Epub 2010 Dec 30.

The pedunculopontine nucleus as a target for deep brain stimulation

Hamani C, Moro E, Lozano AM.

J Neural Transm (Vienna). 2011 Oct;118(10):1461-8. doi: 10.1007/s00702-010-0547-8. Epub 2010 Dec 31.

Gender distribution of patients with Parkinson's disease treated with subthalamic deep brain stimulation; a review of the 2000-2009 literature

Hariz GM, Nakajima T, Limousin P, Foltynie T, Zrinzo L, Jahanshahi M, Hamberg K.

Parkinsonism Relat Disord. 2011 Mar;17(3):146-9. doi: 10.1016/j.parkreldis.2010.12.002. Epub 2010 Dec 30.

[Building and validation of a test evaluating verbal recognition memory: The Forty test (f40)]

Marqué A, Hommet C, Constans T, Perrier D, Bardet F, Chaput M, Mondon K.

Rev Neurol (Paris). 2011 Apr;167(4):324-30. doi: 10.1016/j.neurol.2010.10.003. Epub 2010 Dec 30.

Nonmotor disturbances in Parkinson's disease

Bassetti CL.

Neurodegener Dis. 2011;8(3):95-108. doi: 10.1159/000316613. Epub 2010 Dec 23.

LRRK2 as a therapeutic target in Parkinson's disease

Tan EK, Schapira AH.

Eur J Neurol. 2011 Apr;18(4):545-6. doi: 10.1111/j.1468-1331.2010.03305.x. Epub 2010 Dec 29.

Parkinson's disease dementia and potential therapeutic strategies

Caviness JN, Lue L, Adler CH, Walker DG.

CNS Neurosci Ther. 2011 Feb;17(1):32-44. doi: 10.1111/j.1755-5949.2010.00216.x. Epub 2010 Dec 28.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias